Delving into the Latest Updates on PDL1/VISTA inhibitors(China Pharmaceutical University) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Compound P17(China Pharmaceutical University)

Target

PDL1 x VISTA

Action

inhibitors

Mechanism

PDL1 inhibitors(Programmed death-ligand 1 inhibitors), VISTA inhibitors(V-domain Ig suppressor of T-cell activation inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

China Pharmaceutical University

Active Organization

China Pharmaceutical University

Inactive Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC22H24N4O4

InChIKeyQSHNMTVUJAVARU-IBGZPJMESA-N

CAS Registry2978623-09-3

Inhibiting the activity of immune checkpoint proteins to reignite the antitumor activity of immune cells has emerged as a pivotal strategy. PD-L1 and VISTA, as critical proteins governing immune regulation, are concurrently upregulated under conditions such as hypoxia. Through a rational drug design process, P17, a dual-target inhibitor for PD-L1 and VISTA is identified. This inhibitor blocks the signaling pathways of both PD-L1 and VISTA at the protein and cellular levels, thereby reactivating the antitumor function of T cells. P17 displays encouraging attributes in terms of druggability and safety assessments. Notably, P17 demonstrates superior antitumor efficacy compared to single-target inhibitors at equivalent doses in in vivo experiments. More crucially, P17 significantly enhances the infiltration of immune cells. This study not only validates the effectiveness of a dual-target inhibitor strategy against PD-L1 and VISTA, but also identifies P17 as a promising candidate molecule with significant therapeutic potential.

100 Deals associated with PDL1/VISTA inhibitors(China Pharmaceutical University)

Login to view more data